08:57 AM EDT, 07/09/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Wednesday it has signed an agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria, to supply its HIV prevention drug, Lenacapavir, in enough doses to reach up to two million people over three years in countries supported by the Global Fund, at no profit to Gilead.

Lenacapavir is Gilead's twice-yearly injectable HIV-1 capsid inhibitor, developed to prevent HIV as a pre-exposure prophylaxis.

The collaboration with the Global Fund is being taken to ensure supply until licensed generic versions of lenacapavir are available in countries covered by its voluntary licensing program, Gilead said.